3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
2
Thoracic
1
Sarcoma
1
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Breast Neoplasms
37
Ovarian Neoplasms
8
Breast Neoplasms, Male
8
Lung Neoplasms
7
Carcinoma, Non-Small-Cell Lung
7
Triple Negative Breast Neoplasms
6
Carcinoma, Ovarian Epithelial
6
Pancreatic Neoplasms
4
Colorectal Neoplasms
4
Stomach Neoplasms
3
Small Cell Lung Carcinoma
3
Colonic Neoplasms
3
Uterine Cervical Neoplasms
2
Testicular Neoplasms
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Neoplasm Metastasis
2
Lymphoma, T-Cell, Cutaneous
2
Lymphoma, Non-Hodgkin
2
Lymphoma, Mantle-Cell
2
Lymphoma, Large-Cell, Immunoblastic
2
Lymphoma, Large B-Cell, Diffuse
2
Lymphoma, Follicular
2
Lymphoma, B-Cell, Marginal Zone
2
Lymphoma
2
Leukemia, Myeloid, Acute
2
Leukemia, Lymphocytic, Chronic, B-Cell
2
Kidney Neoplasms
2
Inflammatory Breast Neoplasms
2
Hodgkin Disease
2
Carcinoma, Renal Cell
2
Interventions
pembrolizumab
18
Nivolumab
12
atezolizumab
5
Ipilimumab
4
Cyclophosphamide
4
fludarabine
3
Paclitaxel
3
Magnetic Resonance Spectroscopy
3
Fluorodeoxyglucose F18
3
Docetaxel
3
Carboplatin
3
spartalizumab
2
cabozantinib
2
avelumab
2
aldesleukin
2
Specimen Handling
2
Interleukin-2
2
Immunoglobulin G
2
zanidatamab
1
veliparib
1
trastuzumab deruxtecan
1
tislelizumab
1
temsirolimus
1
sargramostim
1
sacituzumab govitecan
1
rucaparib
1
regorafenib
1
poly ICLC
1
pemigatinib
1
liposomal doxorubicin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma, Transitional Cell
×
sargramostim
×
Breast
×
Clear all
NCT05269381
2026-03-12
PNeoVCA
Mayo Clinic
Phase 1/2
Recruiting
132 enrolled